Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
1/23/2025 | $261.00 → $200.00 | Buy → Sell | Goldman |
12/20/2024 | $280.00 | Overweight | Stephens |
12/4/2024 | $275.00 | Outperform | Mizuho |
11/19/2024 | $235.00 | Sector Perform | Scotiabank |
10/8/2024 | $286.00 | Outperform | Exane BNP Paribas |
8/27/2024 | $256.00 → $273.00 | Buy | Citigroup |
7/9/2024 | $240.00 | Buy | BTIG Research |
10/25/2023 | $211.00 → $229.00 | Equal Weight → Overweight | Wells Fargo |
S-8 - VEEVA SYSTEMS INC (0001393052) (Filer)
10-K - VEEVA SYSTEMS INC (0001393052) (Filer)
8-K - VEEVA SYSTEMS INC (0001393052) (Filer)
SC 13G/A - VEEVA SYSTEMS INC (0001393052) (Subject)
SC 13G/A - VEEVA SYSTEMS INC (0001393052) (Subject)
SC 13G/A - VEEVA SYSTEMS INC (0001393052) (Subject)
PLEASANTON, Calif., Jan. 25, 2022 /PRNewswire/ -- Veeva Systems (NYSE:VEEV) today announced the appointments of Tim Cabral, Priscilla Hung, Tina Hunt, and Marshall Mohr to its board of directors. Veeva also announced Ron Codd will retire from the board at the end of his current term in June 2022. "We are pleased to welcome Tim, Priscilla, Tina, and Marshall, who bring a range of experience in life sciences and enterprise software to the Veeva board," said Veeva CEO Peter Gassner. "I would also like to thank Ron Codd for a decade of partnership and contributions to Veeva." Th
BARCELONA, Spain--(BUSINESS WIRE)--Veeva Systems (NYSE: VEEV) announced that in an overwhelming majority vote, 99% of voting shareholders support the company’s proposal to become a public benefit corporation (PBC), including the vast majority of Veeva’s largest shareholders. With shareholder approval, Veeva will become a public benefit corporation on Feb. 1, 2021, making it the first publicly traded company and largest-ever to convert to a PBC. As a PBC, Veeva will remain a for-profit corporation but will be legally responsible to balance the interests of multiple stakeholders, including customers, employees, partners, and shareholders. It will also broaden its certificate of inc
PLEASANTON, Calif.--(BUSINESS WIRE)--Please replace the release with the following corrected version due to multiple revisions. The updated release reads: VEEVA BECOMES FIRST PUBLIC COMPANY TO CONVERT TO A PUBLIC BENEFIT CORPORATION Aligns legal charter with company’s long-term view and commitment to all stakeholders, including customers, employees, and shareholders Proposal passes by landslide as Veeva garners widespread support for leading in stakeholder capitalism Veeva Systems (NYSE: VEEV) announced that in an overwhelming majority vote today, 99% of voting shareholders support the company’s proposal to become a public benefit corporation (PBC), including the vast majorit
Fiscal Year 2025 Total Revenues of $2,746.6M, up 16% Year Over YearQ4 Total Revenues of $720.9M, up 14% Year Over Year Fiscal Year 2025 Subscription Services Revenues of $2,284.7M, up 20% Year Over YearQ4 Subscription Services Revenues of $608.6M, up 17% Year Over Year PLEASANTON, Calif., March 5, 2025 /PRNewswire/ -- Veeva Systems Inc. (NYSE:VEEV), a leading provider of industry cloud solutions for the global life sciences industry, today announced results for its fourth quarter and fiscal year ended January 31, 2025. "It was an outstanding quarter and year of execution and i
PLEASANTON, Calif., Feb. 12, 2025 /PRNewswire/ -- Veeva Systems (NYSE:VEEV) will announce financial results for its fourth quarter and full fiscal year, which ended January 31, 2025, after market close on March 5, 2025. Veeva will host a conference call and webcast that day at 2:00 p.m. PT (5:00 p.m. ET) to discuss its financial results. Veeva will post prepared remarks to its investor relations website at https://ir.veeva.com at approximately 1:05 p.m. PT (4:05 p.m. ET). A webcast replay will be available on the website following the live event. Event: Veeva Systems' Fiscal 2025 Fourth Quarter and Full Year Results Conference Call Date: Wednesday, March 5, 2025 Time: 2:00 p.m. PT (5:00 p.m
Total Revenues of $699.2M, up 13% Year Over YearSubscription Services Revenues of $580.9M, up 17% Year Over Year PLEASANTON, Calif., Dec. 5, 2024 /PRNewswire/ -- Veeva Systems Inc. (NYSE:VEEV), a leading provider of industry cloud solutions for the global life sciences industry, today announced results for its third quarter ended October 31, 2024. "It was a great quarter of innovation and excellent execution across the board," said CEO Peter Gassner. "Especially significant was the hard work for the long term. We deepened a number of large, highly strategic relationships and a
4 - VEEVA SYSTEMS INC (0001393052) (Issuer)
4 - VEEVA SYSTEMS INC (0001393052) (Issuer)
4 - VEEVA SYSTEMS INC (0001393052) (Issuer)
Goldman downgraded Veeva Systems from Buy to Sell and set a new price target of $200.00 from $261.00 previously
Stephens initiated coverage of Veeva Systems with a rating of Overweight and set a new price target of $280.00
Mizuho initiated coverage of Veeva Systems with a rating of Outperform and set a new price target of $275.00
Major new initiative will add AI to Veeva applications and the Veeva Vault Platform to help automate critical industry-specific functions and improve productivity from clinical to commercial PLEASANTON, Calif., April 29, 2025 /PRNewswire/ -- Veeva Systems (NYSE:VEEV) today announced Veeva AI, a major new initiative that adds AI to the Veeva Vault Platform and Veeva applications to help life sciences companies automate tasks and improve employee productivity using AI Agents and AI Shortcuts. Veeva AI provides a fast and efficient way to introduce application-specific AI Agents based on large language models (LLMs) into existing Veeva applications and enable end users with AI Shortcuts. Veeva
Cloud CTMS software to improve research site efficiency and integrate seamlessly with sponsors PLEASANTON, Calif., April 1, 2025 /PRNewswire/ -- Veeva Systems (NYSE:VEEV) today announced Veeva SiteVault CTMS, a clinical trial management system for research sites that is integrated with SiteVault eISF and SiteVault eConsent to allow sites to comprehensively manage clinical trials within one main system. Integration with sponsors using Veeva's Clinical Platform gives sites seamless bidirectional data flow to sponsors to reduce manual processes and increase efficiency. "We need t
Specialized CRO standardizes on Veeva RTSM to drive operational efficiency and faster study timelines PLEASANTON, Calif., March 19, 2025 /PRNewswire/ -- Veeva Systems (NYSE:VEEV) today announced that Indero, formerly Innovaderm Research, successfully launched its 40th RTSM study on Veeva RTSM. By standardizing with Veeva RTSM, Indero has strengthened its clinical trial operations, harnessing advanced RTSM capabilities and expert support to drive efficiency, enhance process consistency, and streamline execution. "As we continue to optimize our clinical trial operations, Veeva R